ATAI Life Sciences N.V. (ATAI)
|Net Income (ttm)||-178.63M|
|Trading Day||July 30|
|Day's Range||14.42 - 16.12|
|52-Week Range||14.42 - 22.91|
Atai Launches New "Nose-To-Brain" Drug Delivery Company To Interact With Its Portfolio Of Psychedelics Subsidiaries
Atai Life Sciences (NASDAQ:ATAI) is launching a new company that will interact with its portfolio of psychedelics and tech start-ups looking at novel mental health treatments. InnarisBio Inc., as the co...
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a m...
BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatmen...
Investment Banks Bullish On Psychedelics Co Atai Life Sciences: Cantor, Credit Suisse, Citigroup, Cowen, Aegis And Ot...
This week, a number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ:ATAI), the Peter Thiel-backed biotech exploring a host of psychedelic compounds and treatment...
Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Menta...
CHICAGO, July 15, 2021 /PRNewswire/ -- P alo Santo , the leading U.S.-based psychedelic investment fund, announced its launch with an initial $35 million in capital raised and an active portfolio of 20...
atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for va...
It's off to a running start.
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday. The Berlin-based company is joining an exclusive group of start-ups in the psychedelics sect...
The German biotech's initial public offering was priced Thursday night at $15 per share, the high end of the expected range.
Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of ...
(Reuters) -Shares of Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitaliz...
Atai Life Sciences founder on using psychedelics to treat mental illness
Atai Life Sciences, a biotech company that uses psychedelics to treat mental illness, is going public on the Nasdaq Friday. Christian Angermayer, Atai Life Sciences founder, joined "Squawk Box" on Frida...
BERLIN, June 17, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today ...
BERLIN, June 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the c...
ATAI Life Sciences N.V. has filed to go public with an IPO on the NASDAQ.
ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. It is expected that more than 50% of the U.S. population will be diagnosed with a mental health disorder at some point in their lifetime, with increasing incidence ascribed to the COVID-19 pandemic. We founded atai Life Sciences in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooke... [Read more...]
|IPO Date |
Jun 18, 2021
|Stock Exchange |
|Ticker Symbol |